Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared a post on X:
“Letter on the DB06 trial by ASCO/CAP members out in NEJM. Recommendation to report HER2 IHC 0 as ‘with no staining’ or ‘with staining’ to ascertain eligibility for T-DXd. Call to action for the sponsors to share specimens for testing quantitative assays.”
“Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer”
More posts featuring Paolo Tarantino.
